Introduction
Nowadays, cancer has become one of the most common causes of death around the world, and chemotherapy is still a commonly used strategy in cancer therapy. [1] However, most anticancer drugs show poor water solubility, limited stability, rapid blood clearance and severe side effects, which largely limit their clinic application. [2] In recent years, there are numerous strategies for optimizing these suboptimal pharmacokinetic properties. [3] Engineering the poorly soluble drugs with carrier materials and surfactants into drug nanoparticles (NPs) provides numerous routes to improve its bioavailability. [4, 5] With the protection of the carrier and the surfactant, NPs can not only increase the stability of the drug, but also slowly release the drug and prolong half-life of the drug. It is well known that the PEGylation was favored for water dispersibility and stability. [6] Hence, it is a very great progress to fabricate the drug into NPs.
Among all the suboptimal pharmacokinetic properties, severe side effects were the biggest problem in clinic application. [7] It was because the anticancer drug would attack the healthy cells as well as the cancer cells. Hence, improving the drug targeting property would decrease the side effect. It has long been believed that folate (FA) is a good target molecule because of the over-expression FA receptors in cancer cells. [8, 9] The NPs with the functionalization of FA could latch onto FA receptors of the cancer and thus enhance their cellular uptake. Herein, we used a dialysis technique to prepared the HCPT loaded, MPEG-PLA-FA (monomethoxy polyethylene glycol-polylactide-folate) modified polymeric NPs, which possessed improved the drug sustained release properties. The characteristics of MPEG-PLA-FA copolymer were evaluated by Fourier transform infrared spectroscopy (FT-IR). The physicochemical characteristics of the self-assembled HMPF NPs including particle size, zeta potential, morphology and drug release were characterized by dynamic light scattering (DLS), electrophoretic light scattering (ELS), scanning electron microscopy (SEM), transmission electron microscopy (TEM) and fluorescence spectrophotometry.
Methods

Materials.
All chemicals were analytical grade and used as received without further purification. The ultrapure water (18 MΩ•cm -1 ) was used throughout the work. The 10-HCPT (purity > 99%) was purchased from Lishizhen Pharmaceutical Co., Ltd. The monomethoxy (polyethylene glycol)-poly (lactide-co-glycolide) (MPEG-PLA, PEG: 10%, 5000 Da, PLA: 28000 Da, 85/15) was obtained from Daigang Biotechnology Co., Ltd.
Preparation of the MPEG-PLA-FA conjugation.
MPEG-PLA-FA was synthesized via the esterification reaction between the carboxyl group of FA molecule and the hydroxyl group (derived from PLA) of MPEG-PLA polymer. 0.025 mmol of FA dissolved in 10 mL of dimethylsulfoxide (DMSO) was reacted with 0.05 mmol of NHS and 0.05 mmol of DCC under nitrogen atmosphere at room temperature for 12 h. The activated folic acid was reacted with 0.012 mmol of MPEG-PLA dissolved in 5 mL of DMSO. The reaction was performed under nitrogen atmosphere at room temperature for 4 h. The mixture was filtered and then dialyzed against PBS/DI water to remove excess FA and other byproducts and lyophilized for 24.
Preparation of the HMPF NPs.
The HMPF NPs were prepared by a facile dialysis method. In brief, 100 mg of MPEG-PLA-FA and 10 mg of HCPT were dissolved in 10 mL of DMSO, and the mixture was used as the organic phase. Subsequently, the resulting organic phase was then introduced into a dialysis bag and dialyzed against 1, 000 mL of water as the aqueous phase for 8 h. The HMPF NPs were lyophilized for 24 h using a freeze drier and stored at 4°C for use. The HMP NPs were prepared in a similar way by using MPEG-PLA instead of MPEG-PLA-FA.
Characterization.
The morphology of HMPF NPs was examined by SEM (UV-70) at 10 kV and by TEM (JEM-2100) at 200 kV. The average particle size and size distribution of the NDs were determined by photon correlation spectroscopy with a Malvern Zetasizer Nano-ZS (Malvern Instruments, Malvern) at 25°C under suitable dilution conditions. Measurements were repeated for three times to get the consistent results. The amount of HCPT entrapped in the particles was determined indirectly by fluorescence spectrophotometry (Fluoromax-4). All samples were assayed at 383 nm. The weight of the drug entrapped in the particles was calculated by the calibration curve. [4] 
In vitro drug release studies.
The in vitro drug release studies of particles were performed using the dialysis technique. The HCPT-loaded NPs were dispersed in PBS (10 mL) and placed into a pre-swelled dialysis bag (MWCO 3500 Da). The dialysis bag was then immersed in 0.1 M PBS at pH 6.8, 7.4, and 8.0, and oscillated continuously in a shaker incubator (100 rpm) at 37°C. All samples were assayed by fluorescence spectrophotometry. Free HCPT at the equivalent concentrations were used for comparison.
Results and discussion
Preparation and characterization of the HMPF NPs.
First, we synthesized the MPEG-PLA-FA conjugation via the esterification reaction between the carboxyl group of FA molecule and the hydroxyl group (derived from PLA) of MPEG-PLA polymer (Fig. 1A) . Fig. 1B shows the FT-IR spectra of MPEG-PLA and MPEG-PLA-FA. Compared to MPEG-PLA, signal intensity at 1744 cm -1 clearly increased in the IR spectrum of MPEG-PLA-FA, corresponding to C=O stretching vibration of ester bond. In addition, the characteristic peaks of FA at 2561 cm -1 and 666 cm -1 appeared in the IR spectrum of MPEG-PLA-FA, corresponding to hydroxy and benzene rings of FA. These results indicated FA was successfully conjugated to hydroxyl group of MPEG-PLA via ester bond. . The HMPF NPs was prepared via the dialysis method. Both HCPT and MPEG-PLA-FA were dissolved in dimethyl formamide (DMF), and the mixture was dialyzed against water for 6 h. Due to the good miscibility between DMF and water, DMF was gradually removed and slowly replaced with water in the dialysis process. To attain the minimal energy state, the hydrophobic PLA and HCPT assembled together and formed a core, while the hydrophilic PEG and FA extended to the aqueous environment to form a shell.
The morphology of HMPF NPs were evaluated by SEM and TEM. The SEM image ( Fig. 2A ) shows that the HMPF NPs are spherical with a relatively smooth surface. The TEM image (Fig. 2B) and the result of DLS shows that the NPs are homogeneous solid particles with an average diameter of about 230.4±8.7 nm and a zeta potential of -8.9±0.8 mv. The determined drug entrapment efficiency and drug-loaded content of HMPF NPs determined by fluorescence spectrophotometry were 67.77 ± 0.57% and 8.23 ± 0.07%, respectively. The in vitro release study of the HMPF NPs was performed in PBS at pH 6.8, 7.4, and 8.0. As shown in Fig. 3 , the HMPF NPs exhibited a slow, prolonged release profile over a period of 160 h and there was no dramatic initial burst release. This was because the HCPT was encapsulated in the inner part of the nanoparticles. The release of HCPT molecules was maximum and the fastest at pH 8.0.
Because HCPT would open the ring structure in the alkaline pH environment to carboxylate form and the solubility would greatly increase. But it still exhibited a controlled release manner, which demonstrated that the HMPF NPs could protect HCPT and thus prolong its half-life. 
Conclusions
In this study, we developed a simple but successful method to obtain the HMPF NPs with fine characteristics for drug delivery. The HMPF NPs presented better dispersibility and stability properties and drug sustained release properties. The results obtained in this study indicate that these NPs might become a promising drug delivery system for HCPT.
